OUTREACH2
04 May 2022
Trial Summary
An Open Label, Randomised Phase 2 Study to Evaluate the Safety and Efficacy of MTL CEBPA Administered in Combination with Sorafenib or Sorafenib Alone, in TKI Naive participants with Previously Treated Advanced Hepatocellular Carcinoma (HCC) and Hepatitis B or Hepatitis C Virus (OUTREACH2)
Acronym:
OUTREACH2
ACTRN/NCT /ethics:
NCT04710641
Scientific title:
Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2)
Sponsor / Cooperative group:
Mina Alpha Limited
Trial & Patient Characteristics
| Cancer Type | Other |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Liver |
| Cancer Stage | Locally Advanced |
| Anticipated Start Date | 2022-01-01 |
| Anticipated End Date | 2025-05-01 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Stella Papacharissiou |
| stella.papacharissiou@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Vy Broadbridge |
| Recruitment Status | Not Yet Recruiting |